ChiCTR2200057534
Untitled Trial
A prospective, multi-center, phase II study of camrelizumab in combination with apatinib and fluzoparib in second-line chemotherapy and immunotherapy for advanced NSCLC that has progressed
chinese peoples liberation army general hospital·Not Applicable·Chinese Clinical Trial RegistryNot yet recruiting
View on Chinese Clinical Trial Registry →Study focus
- Disease/Condition
- Non-small cell lung cancer
Sponsor & location
- Primary sponsor
- chinese peoples liberation army general hospital
- Funder
- This trial drug is sponsored by Jiangsu Hengrui Pharmaceutical Co., Ltd.
- Location
- China
Timeline & enrollment
- Phase
- Not Applicable
- Start date
- N/A
- End date
- Apr 30, 2025
ICD-10 classifications
Secondary malignant neoplasm of lungMalignant neoplasm: Lower lobe, bronchus or lungMalignant neoplasm: Middle lobe, bronchus or lungMalignant neoplasm: Bronchus or lung, unspecifiedMalignant neoplasm of bronchus and lung
Data source
- Registry
- Chinese Clinical Trial Registry
- Trial ID
- ChiCTR2200057534
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for ChiCTR2200057534 through Pure Global AI's free database. This Not Applicable trial is sponsored by chinese peoples liberation army general hospital and is currently Not yet recruiting. The study focuses on Non-small cell lung cancer.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Chinese Clinical Trial Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.